| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary targets of D-4-hydroxyphenylglycine are not biological receptors but rather chemical reaction partners in antibiotic synthesis. The compound serves as a side chain precursor for semisynthetic β-lactam antibiotics. Its incorporation into the antibiotic structure provides the necessary pharmacophore for antibacterial activity.
|
|---|---|
| ln Vitro |
In vitro activity for D-4-hydroxyphenylglycine refers to its role as a building block for antibiotic synthesis rather than direct biological activity. The compound is used as a raw material in the production of Amoxicillin and Cefadroxil. Its chemical structure is incorporated into these antibiotics, contributing to their antibacterial properties.
|
| ln Vivo |
In vivo activity data are not applicable for D-4-hydroxyphenylglycine as a standalone compound. However, the antibiotics produced from it (Amoxicillin and Cefadroxil) have well-established in vivo antibacterial activity. The compound itself is not used as a therapeutic agent but rather as a synthetic intermediate.
|
| Enzyme Assay |
Non-cellular assays for D-4-hydroxyphenylglycine typically involve characterization of its chemical properties and purity. Standard analytical techniques include NMR spectroscopy, HPLC, and polarimetry to confirm identity, purity, and enantiomeric excess. The compound's specific rotation is measured to verify the D-enantiomer (typically -156° to -161° in 1N HCl).
|
| Cell Assay |
Cellular assays are not applicable for D-4-hydroxyphenylglycine, as it is a chemical intermediate used in antibiotic synthesis rather than a compound studied for biological activity in cell culture. Its use is limited to chemical synthesis and pharmaceutical manufacturing.
|
| Animal Protocol |
In vivo animal experiments are not conducted for D-4-hydroxyphenylglycine, as it is a synthetic intermediate rather than a therapeutic compound. The compound is not administered to animals for any research purpose. Its applications are strictly limited to chemical synthesis and pharmaceutical manufacturing.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for D-4-hydroxyphenylglycine, as it is a chemical intermediate and not a pharmaceutical compound. The compound's molecular weight is 167.16 g/mol. It has a melting point of approximately 240°C (decomposes), a density of 1.396 g/cm³, and a water solubility of 5 g/L at 20°C. It should be stored in a cool, dry place.
|
| Toxicity/Toxicokinetics |
Toxicological data for D-4-hydroxyphenylglycine are limited, as it is a chemical intermediate not intended for human use. Standard laboratory safety precautions should be followed when handling the compound. No significant toxicity has been reported in the available literature. The compound is considered relatively safe for handling in industrial and research settings.
|
| References |
[1]. Yu H, et al. Efficient biocatalytic production of D-4-hydroxyphenylglycine by whole cells of recombinant Ralstonia pickettii. Folia Microbiol (Praha). 2009;54(6):509-515.
|
| Additional Infomation |
D-4-hydroxyphenylglycine is the D-enantiomer of 4-hydroxyphenylglycine. It is a non-protein amino acid found in the golden nematode (Herpetosiphon aurantiacus). It is the enantiomer of L-4-hydroxyphenylglycine and also the zwitterionic tautomer of D-4-hydroxyphenylglycine. D-4-hydroxyphenylglycine has also been reported in Daphnia pulex and Apis cerana, and relevant data are available for reference.
Other information includes D-4-hydroxyphenylglycine's role as one of the most important raw materials used in the production of semisynthetic β-lactam antibiotics, such as Amoxicillin and Cefadroxil. It is also known as D(-)-4-hydroxyphenylglycine and (2R)-2-amino-2-(4-hydroxyphenyl)acetic acid. The compound is available with ≥98.5% purity and is used in the pharmaceutical industry as a key intermediate for antibiotic synthesis. |
| Molecular Formula |
C8H9NO3
|
|---|---|
| Molecular Weight |
167.16
|
| Exact Mass |
167.058
|
| CAS # |
22818-40-2
|
| PubChem CID |
89853
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
365.8±32.0 °C at 760 mmHg
|
| Melting Point |
240 °C (dec.)(lit.)
|
| Flash Point |
175.0±25.1 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.633
|
| LogP |
0.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
164
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O([H])C([C@@]([H])(C1C([H])=C([H])C(=C([H])C=1[H])O[H])N([H])[H])=O
|
| InChi Key |
LJCWONGJFPCTTL-SSDOTTSWSA-N
|
| InChi Code |
InChI=1S/C8H9NO3/c9-7(8(11)12)5-1-3-6(10)4-2-5/h1-4,7,10H,9H2,(H,11,12)/t7-/m1/s1
|
| Chemical Name |
(2R)-2-amino-2-(4-hydroxyphenyl)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 1 mg/mL (5.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9823 mL | 29.9115 mL | 59.8229 mL | |
| 5 mM | 1.1965 mL | 5.9823 mL | 11.9646 mL | |
| 10 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
